Published in PLoS Pathog on December 08, 2016
Genome engineering using the CRISPR-Cas9 system. Nat Protoc (2013) 15.98
Development and applications of CRISPR-Cas9 for genome engineering. Cell (2014) 13.50
Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science (2014) 10.43
Cell cycle and genetic requirements of two pathways of nonhomologous end-joining repair of double-strand breaks in Saccharomyces cerevisiae. Mol Cell Biol (1996) 7.33
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. Cell (2015) 5.97
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
HIV-1 proviral DNA excision using an evolved recombinase. Science (2007) 2.81
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep (2013) 2.48
The role of the non-homologous end-joining pathway in lymphocyte development. Immunol Rev (2004) 2.44
RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A (2014) 2.32
Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J Biol Chem (2014) 2.18
Alteration of Cre recombinase site specificity by substrate-linked protein evolution. Nat Biotechnol (2001) 1.92
Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins. Hepatology (2015) 1.52
Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A (2014) 1.49
Insertion and deletion mutants of FokI restriction endonuclease. J Biol Chem (1994) 1.48
The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids (2014) 1.46
Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun (2015) 1.41
Crystal Structure of Cpf1 in Complex with Guide RNA and Target DNA. Cell (2016) 1.41
Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids (2014) 1.33
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology (2014) 1.29
Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol (2014) 1.26
Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther (2015) 1.17
CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One (2014) 1.16
IFI16 restricts HSV-1 replication by accumulating on the hsv-1 genome, repressing HSV-1 gene expression, and directly or indirectly modulating histone modifications. PLoS Pathog (2014) 1.15
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep (2015) 1.14
CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. J Gen Virol (2014) 1.12
RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A (2014) 1.10
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog (2013) 1.08
Intracellular approach for blocking JC virus gene expression by using RNA interference during viral infection. J Virol (2004) 1.06
The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology (2015) 1.06
CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape. Mol Ther (2016) 1.06
In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochem Biophys Res Commun (2014) 1.04
Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc Natl Acad Sci U S A (2015) 1.03
CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. Cell Rep (2016) 1.03
TALEN-mediated genome editing: prospects and perspectives. Biochem J (2014) 1.01
Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res (2015) 0.99
Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex. Mol Ther (2015) 0.98
Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing. Sci Rep (2016) 0.98
CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep (2015) 0.98
Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J Gen Virol (2015) 0.97
Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Res (2015) 0.97
Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep (2015) 0.94
Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World J Gastroenterol (2015) 0.94
Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. J Gen Virol (2015) 0.93
Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res (2015) 0.92
Probing the sequence space available for HIV-1 evolution. AIDS (2008) 0.91
Differential role of nonhomologous end joining factors in the generation, DNA damage response, and myeloid differentiation of human induced pluripotent stem cells. Proc Natl Acad Sci U S A (2014) 0.90
Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat Biotechnol (2016) 0.90
CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection. PLoS One (2015) 0.90
The Torsin Activator LULL1 Is Required for Efficient Growth of Herpes Simplex Virus 1. J Virol (2015) 0.88
CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus. Mol Ther Nucleic Acids (2015) 0.87
CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep (2015) 0.87
Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. Biomed Res Int (2014) 0.87
Genome editing strategies: potential tools for eradicating HIV-1/AIDS. J Neurovirol (2015) 0.87
The CRISPR/Cas9 genome editing methodology as a weapon against human viruses. Discov Med (2015) 0.86
Inhibition of HSV-1 Replication by Gene Editing Strategy. Sci Rep (2016) 0.85
Retracted Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells. Onco Targets Ther (2014) 0.84
Programmable Site-Specific Nucleases for Targeted Genome Engineering in Higher Eukaryotes. J Cell Physiol (2016) 0.83
In search of the most suitable lentiviral shRNA system. Curr Gene Ther (2009) 0.83
Engineered DNA modifying enzymes: components of a future strategy to cure HIV/AIDS. Antiviral Res (2012) 0.83
Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. Int J Mol Sci (2015) 0.82
CRISPR/Cas9: a double-edged sword when used to combat HIV infection. Retrovirology (2016) 0.82
Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. AIDS (2016) 0.82
Cre Recombinase and Other Tyrosine Recombinases. Chem Rev (2016) 0.82
CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget (2016) 0.81
RNA interference approaches for treatment of HIV-1 infection. Genome Med (2015) 0.81
CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape. Viruses (2015) 0.81
Highly Efficient CRISPR/Cas9-Mediated Cloning and Functional Characterization of Gastric Cancer-Derived Epstein-Barr Virus Strains. J Virol (2016) 0.81
SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. Virology (2016) 0.81
Anti-HIV-1 potency of the CRISPR/Cas9 system insufficient to fully inhibit viral replication. Microbiol Immunol (2016) 0.80
CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLoS Pathog (2016) 0.80
The recombined cccDNA produced using minicircle technology mimicked HBV genome in structure and function closely. Sci Rep (2016) 0.80
Reprogrammed CRISPR-Cas9 targeting the conserved regions of HPV6/11 E7 genes inhibits proliferation and induces apoptosis in E7-transformed keratinocytes. Asian J Androl (2016) 0.80
Viral Determinants of miR-122-Independent Hepatitis C Virus Replication. mSphere (2015) 0.79
CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse. Virus Res (2016) 0.79
Combining CRISPR/Cas9 and rAAV Templates for Efficient Gene Editing. Nucleic Acid Ther (2015) 0.79
Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense. Trends Microbiol (2016) 0.79
Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9. Sci Rep (2016) 0.79
Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther (2016) 0.79
Modulation of Gene Expression by Polymer Nanocapsule Delivery of DNA Cassettes Encoding Small RNAs. PLoS One (2015) 0.77
Occludin-Knockout Human Hepatic Huh7.5.1-8-Derived Cells Are Completely Resistant to Hepatitis C Virus Infection. Biol Pharm Bull (2016) 0.77
Inhibition of clinical pathogenic herpes simplex virus 1 strains with enzymatically created siRNA pools. J Med Virol (2016) 0.77
Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA. Mol Ther (2016) 0.76
Pseudorabies virus can escape from CRISPR-Cas9-mediated inhibition. Virus Res (2016) 0.76
Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer. J Clin Med (2015) 0.76
Gene therapies for hepatitis C virus. Adv Exp Med Biol (2015) 0.76
Negative Feedback Regulation of HIV-1 by Gene Editing Strategy. Sci Rep (2016) 0.75